Literature DB >> 34773253

NLRP3 knockout enhances immune infiltration and inflammatory responses and improves survival in a burn sepsis model.

Mile Stanojcic1, Roohi Vinaik1, Abdikarim Abdullahi1, Peter Chen1, Marc G Jeschke1,2,3,4.   

Abstract

Although sepsis in burn patients is a major contributor to mortality, treatments are not always effective and underlying mechanisms have yet to be completely elucidated. NLRP3 inflammasome orchestrates burn-induced, inflammatory-driven pathophysiologic processes. Here, we determined the mechanism of NLRP3 inflammasome activation on bacterial clearance and mortality in burn sepsis. We obtained tissue and blood from 30 wild-type and 30 Nlrp3-/- mice. Mice were subjected to a two-hit model of 25-30% TBSA scald burn followed by Pseudomonas aeruginosa wound infection 72 hours after injury. We also obtained tissue from 34 adult burn patients (≥18 years of age) with early (0-11 days post-burn) and later (≥12 days post-burn) surgical time-points and ten healthy controls. Murine studies indicated that Nlrp3-/- had 30% improved survival and bacterial clearance at the site of injury and is systemically relative to burn sepsis wild type. Greater macrophage and neutrophil infiltration occurred acutely after infection (12 hours) to the site of injury and adipose tissue. This was followed by increased macrophage and neutrophil infiltration to lymphoid organs and liver beyond the acute phase (24 and 72 hours). Interestingly, Nlrp3 ablation increased acute systemic inflammation (IL-6, TNF-α, IL-1β). Septic burn patients had persistently increased adipose NLRP3 by-product expression beyond the acute phase that was more pronounced in late-onset sepsis. Our findings suggest that Nlrp3 genetic ablation enhanced acute tissue-specific inflammatory responsiveness. Likely, this occurs by paradoxically increasing acute immune infiltration and inflammation with a non-persistent response. Clinically, persistent NLRP3-mediated inflammation occurs in septic versus normal burn patients and potentially detrimentally impacts patient outcomes.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  burns; inflammasome; inflammation; sepsis

Mesh:

Substances:

Year:  2021        PMID: 34773253     DOI: 10.1111/imm.13427

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  2 in total

Review 1.  Two flares of Still's disease after two doses of the ChAdOx1 vaccine.

Authors:  Rashmi Roongta; Sumantro Mondal; Subhankar Haldar; Mavidi Sunil Kumar; Alakendu Ghosh
Journal:  Clin Rheumatol       Date:  2022-03-06       Impact factor: 3.650

Review 2.  New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review.

Authors:  Marie-Therese Holzer; Martin Krusche; Nikolas Ruffer; Heinrich Haberstock; Marlene Stephan; Tobias B Huber; Ina Kötter
Journal:  Rheumatol Int       Date:  2022-08-08       Impact factor: 3.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.